Fetomaternal hemorrhage assessment in Rh-negative patients undergoing dilation and evacuation between 20 and 24 weeks' gestational age: A retrospective cohort study.

Abstract

OBJECTIVE:

To estimate the rate of requiring more than one 300-mcg Rh D immune globulin dose for fetomaternal hemorrhage (FMH) at the time of second-trimester dilation and evacuation (D + E).

STUDY DESIGN:

We performed a retrospective cohort analysis of patients at greater than 20 weeks' gestation who underwent D + E, had Rh D-negative blood type, and received FMH quantification testing.

RESULTS:

Of 25 eligible patients, 24 had negative quantification of FMH; one had positive quantification that did not meet the clinical threshold for additional dosing.

CONCLUSIONS:

The absolute risk of requiring additional Rh D immune globulin after D+E for pregnancies greater than 20 weeks' gestation was 0%.

• Authors: Anne N Flynn, Elizabeth Hoffman, Christina Murphy, Alicia Jen, Courtney A Schreiber, Andrea H Roe
• Journal: Contraception (Contraception) Vol. 110 Pg. 27-29 (06 2022) ISSN: 1879-0518 [Electronic] United States
• PMID: 35192809 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Chemical References

• Rho(D) Immune Globulin

Topics

• Cohort Studies
• Dilatation
• Female
• Fetomaternal Transfusion
• Gestational Age
• Humans
• Pregnancy
• Retrospective Studies
• Rh Isoimmunization
• Rho(D) Immune Globulin (therapeutic use)